20:33:35 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Bio-Works Technologies är verksamma inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.


2023-02-17 Bokslutskommuniké 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-20 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-24 Ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 Årsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-18 Ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-10-18 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-27 Ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-19 Kvartalsrapport 2018-Q2
2018-05-21 Ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 Årsstämma 2018
2018-02-19 Bokslutskommuniké 2017
2020-03-31 08:30:00

Bio-Works Technologies (Nasdaq First North) has signed a distribution agreement with the Mumbai headquartered Arihant Innochem Pvt Ltd to import, store, distribute, market, promote and sell all of its products in India including Bangladesh, Sri Lanka and Nepal.

Bio-Works is continuing the strategy to expand its presence in the Asian region addressing the development of biosimilars and biopharmaceuticals in the Asian countries. India has a well-established biosimilar development and manufacturing foothold as well as in vaccines delivering on innovation and low-cost manufacturing for unmet medical needs worldwide. Furthermore, Indian biopharmaceutical companies have come a long way the last ten years, building up tremendous experience and expertise in biomanufacturing and bioprocess development. This agreement will enable Bio-Works to expand its reach across India and South Asia, leveraging Arihant Innochem's networks and customer base.  

Bio-Works' third generation proprietary agarose resins, WorkBeads™, are specifically developed with commercial scale manufacturing in mind. WorkBeads generally offers faster mass transport, higher yields and purity than competitors with its stronger and more rigid agarose beads with optimal porosity, offering opportunities for process intensification.

"Bio-Works' offers an innovative and true alternative for biomanufacturing customers in India and beyond. The initial response on the Indian market has been very encouraging. Arihant Innochem is a strong partner for us as they fully understand our business cycles and have great access to all major biotech and biopharma companies, both at the purchasing department and at bioprocess development," says Mr Mats Johnson, Bio-Works' CEO.

Arihant Innochem Pvt Ltd has more than 20 years' experience of distributing products from international partner to the healthcare sector in India as well as neighbouring countries including the Gulf states. With Headquarter and laboratories in Mumbai the company also have sales office in Hyderabad and Noida, next to New Delhi. Arihant Innochem operates both bonded and regular temperature-controlled warehouses offering Indian customers in SEZ additional benefits as well as the necessary security of supply for customers in commercial scale manufacturing. Its tech support team and local bioprocess experts provides customers with local support and services.

"Arihant Innochem is very excited to enter into the bioprocess business by signing this agreement with Bio-Works bringing its innovative products to India and beyond benefitting development and manufacturing of novel biotherapeutics and vaccines. By leveraging Bio-Works' Asia Team and our local bioprocess experts we anticipate penetrating the Indian market in a fast pace offering real alternatives of agarose-based chromatography resin ", says Mr Jinesh K Shah, Managing Director and Founder of Arihant Innochem.

For more information please visit Bio-Works' homepage, www.bio-works.com or contact Mr Mats Johnson, CEO for Bio-Works, e-mail: mats.johnson@bio-works.com,telephone: +46 70 516 53 37.

About Bio-Works

Bio-Works designs, develops, manufactures and supplies innovative leading-edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. Bio-Works' agarose based high performance products are used for purification in the life science research phases as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. The Bio-Works' headquarter with R&D and manufacturing is located in Uppsala Business Park in Uppsala, Sweden and the company processes and a Quality Management System follows the standards of ISO 9001:2015. The company's share is listed on Nasdaq First North. FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se,is appointed Certified Adviser.

About Arihant Innochem.

Arihant Innochem Pvt. Ltd. (formerly Arihant Trading Company) is a family owned independent business enterprise founded in 1989. Over the decades, Arihant Innochem has evolved as a trusted associate of pharma companies as a supplier of specialty excipients in India and neighbouring countries. Arihant Innochem also represent personal care, homecare and food ingredients manufacturers and suppliers from all over the world. The excipient product portfolio of Arihant boasts of a unique combination of conventional and niche products and represent the world's leading specialty chemical producers, namely, Lubrizol, Shin-Etsu, Asahi Kasei, Pharmatrans, Freund, Omya in the Pharmaceutical sector. The customer base is essentially all leading Indian biopharma and pharma companies as well as vaccine producers. For more information, please visit Arihant Innochem Pvt. Ltd. homepage,  www.arihantinnochem.com or contact Dr. Sameer Padhye; email: sameer.p@arihantinnochem.com